{"id":"matching-placebo-to-seltorexant","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Seltorexant is an orexin 2 receptor antagonist that promotes sleep by blocking orexin signaling in the central nervous system. The matching placebo is an inert formulation manufactured to be indistinguishable from the active drug in appearance, taste, and administration to maintain blinding in clinical trials. This placebo serves as the control arm in Phase 3 studies evaluating Seltorexant's efficacy and safety in insomnia.","oneSentence":"This is a matching placebo control formulation designed to mimic Seltorexant, an orexin 2 receptor antagonist used in sleep disorder trials.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:20:18.134Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Matching placebo control for Seltorexant clinical trials (not a therapeutic agent)"}]},"trialDetails":[{"nctId":"NCT06559306","phase":"PHASE3","title":"Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-07-25","conditions":"Depressive Disorder, Major","enrollment":752},{"nctId":"NCT04513912","phase":"PHASE3","title":"A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-09-15","conditions":"Depressive Disorder, Major","enrollment":757},{"nctId":"NCT04532749","phase":"PHASE3","title":"A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-09-15","conditions":"Depressive Disorder, Major","enrollment":212},{"nctId":"NCT03375203","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-11-23","conditions":"Insomnia Disorders","enrollment":365},{"nctId":"NCT03321526","phase":"PHASE2","title":"A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-12-12","conditions":"Depressive Disorder, Major","enrollment":107},{"nctId":"NCT03227224","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-08-16","conditions":"Depressive Disorder, Major","enrollment":287},{"nctId":"NCT02464046","phase":"PHASE2","title":"Study to Evaluate Efficacy, Safety and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder Without Psychiatric Comorbidity","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-07-27","conditions":"Insomnia","enrollment":28},{"nctId":"NCT03374475","phase":"PHASE1","title":"A Study to Investigate the Antidepressant Mechanism-of-action of JNJ-42847922 in Participants With Major Depressive Disorder","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-01-05","conditions":"Depressive Disorder, Major","enrollment":140},{"nctId":"NCT04533529","phase":"PHASE3","title":"A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With Seltorexant","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-09-16","conditions":"Depressive Disorder, Major","enrollment":588},{"nctId":"NCT03796026","phase":"PHASE1","title":"A Study to Assess the Effect of Seltorexant Compared to Placebo on Respiration During Sleep in Adult Participants With Obstructive Sleep Apnea","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-01-04","conditions":"Sleep Apnea, Obstructive","enrollment":34},{"nctId":"NCT04951609","phase":"PHASE1","title":"A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents With Major Depressive Disorder Who Have an Inadequate Response to Selective Serotonin Reuptake Inhibitor (SSRI) and Psychotherapy","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-09-02","conditions":"Depressive Disorder, Major","enrollment":31},{"nctId":"NCT05307692","phase":"PHASE2","title":"A Study of Seltorexant in Participants With Probable Alzheimer's Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2022-05-19","conditions":"Alzheimer Disease","enrollment":88},{"nctId":"NCT03494907","phase":"PHASE1","title":"A Study to Evaluate the Effects of Single-dose Seltorexant on Electrocardiogram Intervals in Healthy Adult Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-04-09","conditions":"Healthy","enrollment":52},{"nctId":"NCT02230878","phase":"PHASE1","title":"A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42847922 in Healthy Participants","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2014-05","conditions":"Healthy","enrollment":40},{"nctId":"NCT02578472","phase":"PHASE1","title":"Pilot Study to Evaluate the Duration of Effects on Simulated Car Driving and Cognitive Performance After a Single Dose of JNJ-42847922, Zolpidem and Placebo in Healthy Participants","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2015-11","conditions":"Healthy","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Matching placebo to Seltorexant","genericName":"Matching placebo to Seltorexant","companyName":"Janssen Research & Development, LLC","companyId":"johnson-johnson","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a matching placebo control formulation designed to mimic Seltorexant, an orexin 2 receptor antagonist used in sleep disorder trials. Used for Matching placebo control for Seltorexant clinical trials (not a therapeutic agent).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}